scholarly article | Q13442814 |
P50 | author | Christine Van Broeckhoven | Q2247235 |
Kristel Sleegers | Q28480858 | ||
Jessie Theuns | Q42757468 | ||
Nathalie Brouwers | Q47910878 | ||
Sebastiaan Engelborghs | Q56616406 | ||
Peter Paul De Deyn | Q60327954 | ||
Jean-Jacques Martin | Q87615642 | ||
Ellen Corsmit | Q114405472 | ||
Veerle Bogaerts | Q114407913 | ||
Sally Serneels | Q114407932 | ||
Evelyn De Leenheir | Q114407933 | ||
P2093 | author name string | Kenan Kamali | |
P433 | issue | Pt 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Alzheimer's disease | Q11081 |
P304 | page(s) | 2984-2991 | |
P577 | publication date | 2006-08-24 | |
P1433 | published in | Brain | Q897386 |
P1476 | title | Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease | |
P478 | volume | 129 |
Q36643419 | 100 years and counting: prospects for defeating Alzheimer's disease |
Q34005558 | A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder |
Q36452227 | APOE and AβPP gene variation in cortical and cerebrovascular amyloid-β pathology and Alzheimer's disease: a population-based analysis |
Q46000890 | APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease. |
Q30493543 | Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease |
Q22252311 | Alzheimer mechanisms and therapeutic strategies |
Q35693893 | Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites |
Q53317692 | Amyloid precursor protein gene (APP) variation in late-onset Alzheimer's disease. |
Q39006798 | ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion |
Q36967985 | Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia |
Q37315301 | Contemplating effects of genomic structural variation |
Q22241945 | Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches |
Q33871345 | Current status on Alzheimer disease molecular genetics: from past, to present, to future |
Q37872024 | DNA methylation in neurodegenerative disorders: a missing link between genome and environment? |
Q37622647 | F-box only protein 2 (Fbxo2) regulates amyloid precursor protein levels and processing |
Q42642426 | Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients |
Q35094704 | Genetics of Vascular Dementia |
Q38027808 | Genetics of dementia: update and guidelines for the clinician |
Q34874591 | High glucose promotes Aβ production by inhibiting APP degradation |
Q48302187 | Marginal vitamin A deficiency facilitates Alzheimer's pathogenesis |
Q39054244 | Meserine, a novel carbamate AChE inhibitor, ameliorates scopolamine-induced dementia and alleviates amyloidogenesis of APP/PS1 transgenic mice |
Q42426890 | MicroRNAs can regulate human APP levels. |
Q41665323 | Modifications and Trafficking of APP in the Pathogenesis of Alzheimer's Disease |
Q34584517 | Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model. |
Q37209771 | Molecular genetics of Alzheimer's disease: an update |
Q26750717 | Molecular genetics of early-onset Alzheimer's disease revisited |
Q33575683 | Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastoma |
Q34052418 | Next-generation DNA sequencing-based assay for measuring allelic expression imbalance (AEI) of candidate neuropsychiatric disorder genes in human brain |
Q40863954 | Opposite Dysregulation of Fragile-X Mental Retardation Protein and Heteronuclear Ribonucleoprotein C Protein Associates with Enhanced APP Translation in Alzheimer Disease. |
Q34067152 | Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice |
Q34014237 | Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trials |
Q33830518 | Recent insights into the molecular genetics of dementia |
Q64069671 | Relationship between single nucleotide polymorphisms in the 3'UTR of amyloid precursor protein and risk of Alzheimer's disease and its mechanism |
Q35883202 | Role of common and rare APP DNA sequence variants in Alzheimer disease |
Q59069488 | Somatic APP gene recombination in Alzheimer’s disease and normal neurons |
Q37704614 | The clinical context of copy number variation in the human genome |
Q50345695 | The genetic architecture of autism spectrum disorders (ASDs) and the potential importance of common regulatory genetic variants. |
Q81651107 | The genetics of Alzheimer's disease |
Q33995527 | Understanding microRNAs in neurodegeneration |
Q47431150 | Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease. |